A Phase II Trial of Intravenous Ontak to Treat Epithelial Ovarian Cancer FIGO Stage III or Stage IV, or Extraovarian Peritoneal Carcinoma, Failing or Ineligible for First-Line Therapy.

Trial Profile

A Phase II Trial of Intravenous Ontak to Treat Epithelial Ovarian Cancer FIGO Stage III or Stage IV, or Extraovarian Peritoneal Carcinoma, Failing or Ineligible for First-Line Therapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Aug 2016

At a glance

  • Drugs Denileukin diftitox (Primary)
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Acronyms ONTAK
  • Most Recent Events

    • 25 May 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 25 May 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 13 Apr 2010 Planned end date (1 Dec 2011) as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top